Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMC-S118AI · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Single Ascending Dose | EXPERIMENTAL | Participants receive single ascending doses of IMC-S118AI. |
| Multiple Ascending Dose | EXPERIMENTAL | Participants receive multiple ascending doses of IMC-S118AI. |
| Name | Type | Description |
|---|---|---|
| IMC-S118AI | BIOLOGICAL | IMC-S118AI solution for infusion/injection |
Inclusion Criteria: * Body mass index (BMI): 18 to 25 kg/m2 * History of a diagnosis of T1D * HLA type: HLA-A\*02:01 * Shows signs of remaining beta-cell function Exclusion Criteria: * Non-T1D (type 2 diabetes, monogenic diabetes, and secondary diabetes) * History of recurrent hypoglycaemia due t...
Top 10 of 19 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 6 | PHASE3 | Tirzepatide, Baricitinib, LY4057996, Insulin Lispro |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 5 | PHASE3 | Insulin icodec, Insulin aspart, NNC0194-0499, Semaglutide, NNC0497-0040 |
| Sanofi SA Sponsored ADR | SNY | 12 | PHASE3 | teplizumab/mL, Brivekimig, Frexalimab, Insulin |
| Vertex Pharmaceuticals Incorporated | VRTX | 3 | PHASE3 | VX-880, VX-017, VX-264 |
| vTv Therapeutics, Inc. Class A | VTVT | 2 | PHASE3 | Cadisegliatin |
| SAB Biotherapeutics, Inc. | SABS | 1 | PHASE2 | SAB-142 |
| MannKind Corporation | MNKD | 2 | PHASE2 | Technosphere Insulin |
| Creative Medical Technology Holdings, Inc. | CELZ | 1 | PHASE1 | CELZ-201 |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh | IMCR | 1 | PHASE1 | IMC-S118AI |
| Sana Biotechnology, Inc. | SANA | 1 | EARLY_PHASE1 | UP421 |
IMC-S118AI is an investigational monoclonal antibody being developed by Immunocore Holdings plc for the treatment of Type 1 Diabetes. It is in Phase 1 clinical development and is a biomarker-selected therapy, meaning trial enrollment is guided by a specific biological marker. It has not been approved by the FDA.
IMC-S118AI is being studied as a treatment for Type 1 Diabetes in adults 18 years and older. The Phase 1 program is designed to evaluate the drug in this metabolic indication. It remains investigational and is not approved for any use.
IMC-S118AI targets PD1, also known as programmed cell death protein 1, which is a receptor. By binding to this receptor, the monoclonal antibody is designed to act on PD1-mediated signaling pathways. PD1 is the molecular target of the investigational therapy.
IMC-S118AI is being developed by Immunocore Holdings plc, which trades on the Nasdaq under the ticker IMCR. The company is the sponsor of the clinical program evaluating the drug in Type 1 Diabetes.
IMC-S118AI is in Phase 1 clinical development. It is an investigational monoclonal antibody and has not been approved by the FDA. The Phase 1 program is currently active, with one trial listed and no completed trials.
IMC-S118AI is being evaluated in the Phase 1 study NCT07493122, titled Study of IMC-S118AI in Type 1 Diabetes. The trial is not yet recruiting, is controlled and randomized, and plans to enroll 154 participants aged 18 years and older.